Lexicon Announces Series of Presentations Relating to LX9211, Its Investigational Drug for the Treatment of Diabetic Peripheral Neuropathic Pain (DPNP)
Five upcoming scientific presentations will add to the body of evidence supporting the advancement of LX9211 into late-stage development Phase...